lumateperone Caplyta
Selected indexed studies
- Lumateperone (Caplyta) for schizophrenia. (Med Lett Drugs Ther, 2020) [PMID:32728011]
- Lumateperone: First Approval. (Drugs, 2020) [PMID:32060882]
- Lumateperone (Caplyta) for bipolar depression. (Med Lett Drugs Ther, 2022) [PMID:35921078]
_Worker-drafted node — pending editorial review._
Connections
lumateperone Caplyta is a side effect of
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Lumateperone. (2012) pubmed
- Lumateperone. (2006) pubmed
- Lumateperone: First Approval. (2020) pubmed
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. (2020) pubmed
- Lumateperone (Caplyta) for schizophrenia. (2020) pubmed
- Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial. (2025) pubmed
- Lumateperone (Caplyta) for bipolar depression. (2022) pubmed
- Are Nurses Prescribing Lumateperone (Caplyta)? (2022) pubmed
- Statistical Versus Clinical Significance: A Question About Caplyta (Lumateperone). (2023) pubmed